



## Cytochrome P450 CYP2B6\*6 distribution among Congolese individuals with HIV, Tuberculosis and Malaria infection

Simon Marie Peko<sup>a,b</sup>, Nerly Shirère Gampio Gueye<sup>a,b</sup>, Christevy Vouvoungui<sup>a,b</sup>, Félix Koukouikila-Koussounda<sup>a,b</sup>, Simon Charles Kobawila<sup>b</sup>, David Nderu<sup>c</sup>, Thirumalaisamy P. Velavan<sup>a,c,d</sup>, Francine Ntoumi<sup>a,b,c,\*</sup>

<sup>a</sup> Fondation Congolaise pour la Recherche Médicale (FCRM), Brazzaville, Congo

<sup>b</sup> Faculty of Sciences and Technology, University Marien Ngouabi, Brazzaville, Congo

<sup>c</sup> Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany

<sup>d</sup> Faculty of Medicine, Duy Tan University, Da Nang, Vietnam



### ARTICLE INFO

#### Article history:

Received 9 November 2018

Received in revised form 16 February 2019

Accepted 20 February 2019

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

#### Keywords:

CYP2B6

Cytochrome P 450

HIV

Malaria

Tuberculosis

Republic of Congo

### ABSTRACT

**Background:** The cytochrome P450 CYP2B6\*6 (CYP2B6 c.516G>T; rs3745274) is one of the genetic factors that alters the drug metabolism in antimalarial, antiretroviral and TB first-line drugs. In Central African populations, the distribution of the CYP2B6\*6 variant is poorly documented. This study investigated the distribution of CYP2B6 c.516G>T variant among Congolese individuals.

**Methods:** A total of 418 patients with HIV-1 mono-infection, HIV-1 and Tuberculosis coinfection and symptomatic *P. falciparum* malaria were genotyped for the CYP2B6 c.516G>T SNP using Restriction Fragment Length Polymorphism (RFLP). The allele frequencies and genotype distributions were determined.

**Results:** The CYP2B6 c.516G>T was successfully analysed in 69% (288/418) of the study participants. Among the investigated individuals, the distribution of the major allele CYP2B6\*G was 45% and the minor CYP2B6\*T allele was 55%. Significant differences in genotype distribution were also observed among the studied individuals. The CYP2B6\*GG (rapid metabolizer) genotype was observed in 17% (49/288) followed by CYP2B6\*GT (intermediate metabolizer) 55% (159/288) and CYP2B6\*TT (poor metabolizers) 28% (80/288).

**Conclusion:** This study contributes to increasing understanding on population pharmacogenetics and may help policy makers regulate treatment guidelines in the Congolese population with a high burden of HIV, Malaria and TB.

© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### Introduction

Acquired Immunodeficiency Syndrome (AIDS), Tuberculosis (TB) and Malaria are the leading causes of mortality in Africa. In 2017, a decline in the number of deaths related to these diseases was reported (MOH, 2017). This milestone is, in part, attributed to the prudent use of effective drugs. The emergence and spread of drug-resistant pathogens threaten to reverse these gains.

Combined drug therapy has been widely adopted to circumvent this public health bottleneck. The artemisinin combined therapy (ACT) has been adopted as the first-line antimalarial drug, replacing ineffective first-line drugs such as chloroquine (CQ) and Sulfadoxine-Pyrimethamine (SP). The combination of artesunate (AS) with amodiaquine (AQ) is one of the most widely used ACT regimens. In Republic of Congo, the treatment guideline is the prescription of artesunate–amodiaquine (ASAQ) and artemether-lumefantrine (AL) as first-line and second-line drugs respectively, for the treatment of acute uncomplicated malaria (Ministère de la Santé et de la Population, 2006).

In 2007, Republic of Congo introduced free antiretroviral treatment (ART) for the management of HIV/AIDS within its National Strategic Framework (NSF). Unfortunately, due to delay and/or unavailability of antiretrovirals, there exists a frequent interruption in treatment regimens (Santé, 2013). Efavirenz (EFV), a non-nucleotide reverse transcriptase inhibitor (NNRTI)

\* Corresponding author at: Fondation Congolaise pour la Recherche Médicale, Villa D6, Campus OMS, Djoué, Brazzaville, Congo.

E-mail addresses: [simonmarie8peko@gmail.com](mailto:simonmarie8peko@gmail.com) (S.M. Peko), [ngampio@gmail.com](mailto:ngampio@gmail.com) (N.S.G. Gueye), [vjchristevy@gmail.com](mailto:vjchristevy@gmail.com) (C. Vouvoungui), [felixkoukouikila@yahoo.fr](mailto:felixkoukouikila@yahoo.fr) (F. Koukouikila-Koussounda), [kobawila.simon@gmail.com](mailto:kobawila.simon@gmail.com) (S.C. Kobawila), [dnderu@gmail.com](mailto:dnderu@gmail.com) (D. Nderu), [velavan@medizin.uni-tuebingen.de](mailto:velavan@medizin.uni-tuebingen.de) (T.P. Velavan), [ffntoumi@hotmail.com](mailto:ffntoumi@hotmail.com), [ntoumi@fcrm-congo.com](mailto:ntoumi@fcrm-congo.com) (F. Ntoumi).

combined with two other nucleoside reverse transcriptase inhibitors (NRTIs), is the preferred first-line treatment for HIV/AIDS (Usach et al., 2013).

Genes involved in drug metabolism are important determining factors for drug efficacy and toxicity (Masebe et al., 2012; Michaud et al., 2012; Tozzi, 2010). Cytochrome P450 (CYP) enzyme is an essential enzyme in modulating the drug metabolism. Several single nucleotide polymorphisms (SNPs) had been identified in the CYPs and are associated with altered enzymatic activity thus causing treatment failures (Zanger and Schwab, 2013; Zhou et al., 2009). The human *CYP2B6* is involved in the metabolism of several antibiotics, antimalarial and TB-first line drugs and antiretroviral drugs (Simonsson et al., 2003; Ward et al., 2003). The *CYP2B6* gene is highly polymorphic (Lang et al., 2001) and is characterized by a large inter-individual variability in world populations (Zhou et al., 2017). The functionally characterized *CYP2B6* genetic variants contribute to altered drug metabolism, and differential plasma concentrations, thus individuals being either classified as poor or fast metabolizers (Telenti and Zanger, 2008). The *CYP2B6* genetic variants were documented as useful predictors of pharmacokinetics and drug response (Rakhmanina and van den Anker, 2010). Analysis of these SNPs can be useful to improve drug efficacy and could reduce potential drug toxicity, prior to treatment.

The frequency of the *CYP2B6* SNPs varies also across different ethnicities (Arnaldo et al., 2013; Zhou et al., 2017). Among the studied *CYP2B6* variants, the *CYP2B6* c.516G>T (rs3745274) and *CYP2B6* c.785A>G (rs2279343) are more frequent among African ethnicities and are less frequent among Caucasian and Asian populations (King & Aberg, 2008). The c.516G>T SNP (rs3745274) causes abnormal splicing, decreased expression and activity of the *CYP2B6*\*6 (Hofmann et al., 2008). In Africa, the prevalence of

*CYP2B6* c.516G>T (rs3745274) ranges from 36 to 60% (Klein et al., 2005; Mehlotra et al., 2006; Nyakutira et al., 2008). Rifampicin (RMP) and Isoniazid (INH) are used as first-line drugs for TB treatment. *CYP2B6* is also involved in the metabolism of RMP and INH (Yimer et al., 2011). The *CYP2B6* c.516G>T polymorphism was shown to modulate the TB therapeutic response (Fernandes et al., 2015). The *CYP2B6* c.516G>T has been associated with an increased plasma exposure to EFV (Cortes et al., 2013; Sinxadi et al., 2015; Swart et al., 2013) and increased risk of toxicity in the CNS (Aurpibul et al., 2012; Martin et al., 2014; Sinxadi et al., 2015).

To the best of our knowledge, there is a scarcity of data on the distribution of *CYP2B6* c.516G>T (rs3745274) especially in Central African population. In this context, this study aimed to determine the *CYP2B6* c.516G>T of allele frequencies and genotypes in a cohort of patients who were receiving antimalarial, antiretroviral and TB-first line drugs.

## Materials and methods

### Ethical approval and consent

Ethical approval was obtained from the Institutional Ethics Committee of the Fondation Congolaise pour la Recherche Médicale. Written informed consent was obtained from the study participants and from parents/guardians in case of children, prior to recruitment.

### Study subjects

A total of 418 participants were enrolled in this study (Figure 1). The 418 enrolled subjects were classified in two groups. Among the




Figure 1. Clinical characteristics of the recruited patients in this study cohort.

418 enrolled, 133 were adult patients recruited from Brazzaville anti-Tuberculosis Centre. The remaining 285 participants were children aged between one and ten years old presenting with fever ( $\geq 37.5^\circ\text{C}$ ) at the paediatric ward of the Marien Ngouabi Hospital in Northern Brazzaville, Republic of Congo. Of the 133 recruited, 42 adults were screened for TB and HIV. Among the 42 adults, 20 were positive for both HIV and TB, whereas 22 were positive for HIV alone. Among the 285 febrile children attending the paediatric ward, 28 had symptomatic malaria and 257 were asymptomatic. Two ml of venous blood was collected in EDTA tubes and were transported in cooling cycles and stored under optimal conditions until further use. The baseline data of recruited patients are illustrated in Table 1.

#### CYP2B6\*6 genotyping

Genomic DNA was purified from peripheral whole blood samples preserved with EDTA using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) following manufacturer's instructions. The c.516G>T of the CYP2B6, located in exon 4 of CYP2B6, was genotyped using restriction fragment length polymorphism (RFLP), as described previously (Lang et al., 2001). Briefly, PCR reactions were conducted in a total volume of 50  $\mu\text{l}$  containing 100 ng genomic DNA, 200  $\mu\text{M}$  of dNTPs, 2 pmol of the CYP2B6-4F and CYP2B6-4R primers, and 2.5U Taq polymerase (Promega Corporation). PCR products (5  $\mu\text{l}$ ) were digested with BsrI (New England Biolabs Beverly, MA, USA) for 15 min at 60  $^\circ\text{C}$  and resolved in a 2% agarose gel stained with SYBR Green. The restricted PCR fragment revealed three different genotypes at different product sizes. The CYP2B6 c.516GG (wild-type) showed two bands (241 and 268 bp), followed by CYP2B6 c.516GT (heterozygous) with three bands (241 bp + 268 bp + 509 bp) and the CYP2B6 c.516TT (homozygous mutant) with 509 bp. In order to confirm the methodological approach, twenty representative samples were subjected to Sanger sequencing to confirm the respective genotypes.

#### Data analysis

Data were analysed by STATA v.9.1 (STATA Corporation, Texas, USA) and the level of significance was set at  $P < 0.05$ . Genotype frequencies were determined by simple gene counting and by using the expectation-maximum (EM) algorithm. Chi-square test was executed to determine the differences in allele and genotype distributions between the different sub groups of patients. The significance of deviation from Hardy-Weinberg equilibrium was tested using the random-permutation procedure as implemented in the Arlequin v. 3.5.1.2 software (<http://cmpg.unibe.ch/software/arlequin3/>).

#### Results

The CYP2B6 c.516G>T was successfully genotyped among 288/418 (69%) of the enrolled study subjects. The distribution of alleles

and genotypes in different study groups is given in Table 1. The distribution of the CYP2B6 genotypes were in Hardy-Weinberg equilibrium ( $P = 0.05$ ). The Congolese individuals had a high frequency of genotypes that contribute to intermediate and poor response to treatment (CYP2B6 c.516GT: 55% and CYP2B6 c.516TT: 28% respectively). The genotype distribution was also similar among individuals, when stratified for different infections. The CYP2B6 c.516T allele remains a major allele in the Congolese population.

#### Discussion

There is a paucity of data on the distribution of CYP2B6 c.516G>T variant in the Central African population. This study aimed to determine the CYP2B6 c.516G>T genotype and allele frequencies in patients who were receiving antimalarial, antiretroviral and TB-first line drugs. This first study reports that most of the Congolese individuals carry those CYP2B6 genotypes that modulate the pharmacokinetics of the drugs routinely prescribed such as Rifampicin, Isoniazid, Efavirenz and ACTs.

The Hap Map database reports that the G and T alleles are segregated in sub-Saharan African population as 0.62 and 0.37 respectively. However, when compared to the NCBI Hap Map database, the frequency of the observed SNP variant CYP2B6 c.516G>T (rs3745274) in our study revealed a higher proportion of T variant in the Congolese population compared to that of the wildtype G allele (CYP2B6 c.516G = 0.45 and CYP2B6 c.516T = 0.55).

In Africa, the overall frequency of the G and T alleles is 65% and 35%, respectively, and that of genotypes GG is 42%, GT is 45%, and TT is 13% (Scibona et al., 2015). Arnaldo et al. demonstrated a large variation in the distribution of different CYP2B6 variants in Mozambique including the G516T substitution (Arnaldo et al., 2013). In this study, we observed a higher frequency of CYP2B6 c.516G>T variant in Congolese individuals than those reported from previous studies from African countries (Arnaldo et al., 2013; Gounden et al., 2010; Mukonzo et al., 2009; Nyakutira et al., 2008; Paganotti et al., 2015; Sinxadi et al., 2015; Staehli Hodel et al., 2013). This might be due to a selective pressure and a frequency dependent selection occurring at this locus. Alternatively, heterogeneity among different ethnic populations in this geographical region cannot be excluded (Gounden et al., 2010; Klein et al., 2005; Kwara et al., 2009; Mehlotra et al., 2006; Nyakutira et al., 2008). Corroborating our findings, studies from Uganda and Zimbabwe document a high frequency of the studied CYP2B6\*6 variant (66–68%) (Rajman et al., 2017).

CYP2B6 c.516G>T is considered to be an independent predictor of EFV plasma concentrations in HIV-infected patients. EFV plasma concentrations  $< 1$  mg/L were associated with an increased risk of virological failure, possibly leading to potential drug resistances and poor treatment outcome. Concentrations  $> 4$  mg/l are associated with an increased risk for central nervous system (CNS) impairment and liver toxicity (Marzolini et al., 2001; Zakeri et al., 2014). Few other studies also demonstrate the absence of this

**Table 1**  
CYP2B6 c.516G>T allele and genotype distribution among Congolese patients with HIV and/or TB positive and with malaria.

CYP2B6 c.516G>T	All individuals (n=288)	HIV and/orTB coinfection (n=42)	Symptomatic malaria (n=25)	Non malarial fever (n=221)	P value
Mean age in years (range)	8 (1–54)	36,7 (14–54)	4 (1–10)	3 (1–10)	$P < 0,001$
Male/female ratio	148/139	18/23	14/11	113/108	$P < 0,001$
NP 1					
GG/rapid (%)	49 (17)	11 (26)	3 (12)	35 (16)	
GT/intermediate (%)	159 (55)	17 (41)	14 (56)	128 (58)	
TT/poor (%)	80 (28)	14 (33)	8 (32)	58 (26)	
Allele G (%)	257 (45)	39 (46)	20 (40)	198 (45)	NS
Allele T (%)	319 (55)	45 (54)	30 (60)	244 (55)	

correlation (Fumaz et al., 2005; Read et al., 2009; Takahashi et al., 2007). Previous reports show that CNS side effects occur within the first week of EFV treatment following EFV treatment with the recommended dose (600 mg/per day) and may persist for a long period of time (Dhoro et al., 2015; Vo and Varghese Gupta, 2016). In South Africa, Hong Kong, China, Cambodia and Thailand, elevated EFV plasma concentrations were observed among HIV patients with the CYP2B6 516TT genotype (Pressiat et al., 2017). Nonetheless, genotyping of CYP2B6 c.516G>T serves as a valuable tool for identifying HIV positive individuals who are most likely to develop CNS side effects following EFV treatment (Swart et al., 2015; Swart et al., 2013). In our study, the frequency of genotype 516TT (poor metabolizer) among HIV-1 positive individuals was higher (27,3%) than in Mozambique, South Africa, Burundi, Ethiopia and Tanzania (Arnaldo et al., 2013; Calcagno et al., 2012; Ngaimisi et al., 2013; Sinxadi et al., 2015). However, the distribution of genotype 516TT was in accordance as observed in Cameroon (Paganotti et al., 2015). Taken together, the distribution of the studied CYP2B6 c.516G>T variant may thus help to determine the predictability of EFV concentrations in naïve African patients with HIV.

In Congo, TB-HIV co-infection is 29% and an estimated HIV prevalence is at 3% in the general population (PNLT, 2014). In fact, disease course and a high mortality are influenced by coinfections (Dolin et al., 1994). Although the treatment is free, TB remains a public health burden in the Republic of Congo, esp. in a population living with HIV (MOH). Efavirenz and Rifampicin are the first line treatment prescribed to HIV/TB patients. Since rifampicin is a potential inducer of CYP expression, co-administration with EFV is hypothesized to cause rapid EFV metabolism which may lead to sub-therapeutic EFV plasma concentrations (Breen et al., 2006). However, several studies have rejected this hypothesis (Borand et al., 2014; Kwara et al., 2011; Manosuthi et al., 2013; Ramachandran et al., 2009). In fact, two previous studies reported a subtle increase of EFV plasma concentration in African and African-American patients following EFV-rifampicin treatment (Gengiah et al., 2012; Luetkemeyer et al., 2013). Co-administration of first-line TB drugs are associated with drug induced hepatotoxicity (Xiang et al., 2014; Yimer et al., 2011; Fernandes et al., 2015) Rifampicin (RMP) and Isoniazid (INH) are widely used combination regimens and were shown to associate with hepatotoxicity in TB patients with CYP2B6 c.516TT genotype (Fernandes et al., 2015). In this context, our findings suggest that 40% (8/20) of participants (CYP2B6 c.516TT) with HIV-1 + TB co-infection in this study may likely develop drug induced hepatotoxicity if RMP and INH are administered together. This also implies that co-administration of EFV and RMP would subject these patients to additional side effects as a result of poor drug metabolism and evaluated EFV plasma concentrations (Yimer et al., 2008).

Malaria caused by *P. falciparum* is also a public health concern in Republic of Congo, especially among young children. In Republic of Congo, the national drug policy recommends artesunate–amodiaquine (ASAQ) and artemether–lumefantrine (AL) for the treatment of acute uncomplicated malaria (Ministère de la Santé et de la Population, 2006). The human CYP2B6 gene is also involved in the metabolism of artemisinin and its derivatives (Simonsson et al., 2003). The CYP2B6\*6 allele is associated with increased plasma concentrations of artemisinin and artemether (Kerb et al., 2009). The children with symptomatic malaria infection were also genotyped for CYP2B6\*6. The high frequency of the CYP2B6\*6 homozygous mutant allele (32%) indicates that a large proportion of individuals in this group might be poor metabolizers of artesunate (Kerb et al., 2009; Marwa et al., 2014), resulting in an increased risk to toxicity of the above anti-malarial drugs (Marwa et al., 2014).

Due to poor resource settings, investigations were carried out only to understand the differential distribution of specific CYP2B6

c.516G>T genotype among Congolese individuals with comorbidities. Although other loci in CYP450 enzymes are also involved in modulating the bioavailability of the drugs, this is considered to be a limitation of this study.

## Conclusion

A larger number of infected patients in the study is desirable to confirm the distribution of the CYP2B6\*6 allele and to correlate the genetic findings with the treatment outcome. This first study from Republic of Congo provides a basic understanding on the distribution of CYP2B6 c.516G>T variant and has important repercussions in determining treatment guidelines in a population with a high burden of HIV, Malaria and TB.

## Conflicts of interest

All authors have no conflicts of interest to declare.

## Financial disclosure

This study was funded by CANTAM (Central Africa Network on Clinical Research, EDCTP-RegNet2015-1045) Grant Agreement RIA2016E-1609, a regional network of excellence supported by EDCTP. The authors also acknowledge the support from Congo Assistance Foundation and TOTAL E&P CONGO. The funder has no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. FN, TPV, FKK, are members of CANTAM and PANDORA-ID-Net networks supported by EDCTP and European member states.

## Authors' contributions

FN and FKK designed the study. SMP and NGS participated in the study design, performed the experiments. FKK supervised the study procedures. CV, DN and TPV analysed the data. FN was responsible of overall study. All authors participated in drafting the manuscript.

## Acknowledgements

The authors thank all the study subjects and the parents for their participation. The authors are grateful to all staff members of the Brazzaville anti-tuberculosis treatment centre and the paediatric ward of the Marien NGOUABI hospital. We thank Dr Madinga Kosso Etokabeka for participating in blood collection. We thank Dr Massamba Erick and Dr Laure Ghoma-Linguissi for assisting in study design and for helpful comments while writing the manuscript, respectively. FN, FKK, TPV are members of CANTAM (EDCTP RegNet2015-1045) and PANDORA-ID-Net (EDCTP- RIA2016E-1609).

## References

- Arnaldo P, Thompson RE, Lopes MQ, Suffys PN, Santos AR. Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the Mozambican population. *Malays J Med Sci* 2013;20(4):13–23.
- Aurpibul L, Chotirosnirarn N, Sugandhavesa P, Kosashunhanan N, Thetket S, Supindham T, Supparatpinyo K. Correlation of CYP2B6-516G>T polymorphism with plasma efavirenz concentration and depression in HIV-infected adults in Northern Thailand. *Curr HIV Res* 2012;10(8):653–60.
- Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, Taburet AM. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). *PLoS One* 2014;9(3):e90350. doi:http://dx.doi.org/10.1371/journal.pone.0090350.
- Breen RA, Swaden L, Ballinger J, Lipman MC. Tuberculosis and HIV co-infection: a practical therapeutic approach. *Drugs* 2006;66(18):2299–308.
- Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Di Perri G. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese

- HIV-positive patients using dried sample spot devices. *Br J Clin Pharmacol* 2012;74(1):134–40, doi:<http://dx.doi.org/10.1111/j.1365-2125.2012.04163.x>.
- Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, la Porte CJ. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. *Ther Drug Monit* 2013;35(1):78–83, doi:<http://dx.doi.org/10.1097/FTD.0b013e318274197e>.
- Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P, Masimirembwa C. CYP2B6\*6, CYP2B6\*18, body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. *BMC Pharmacol Toxicol* 2015;16:4, doi:<http://dx.doi.org/10.1186/s40360-015-0004-2>.
- Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990–2000. *Bull World Health Organ* 1994;72(2):213–20.
- Fernandes DC, Santos NP, Moraes MR, Braga AC, Silva CA, Ribeiro-dos-Santos A, Santos S. Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population. *Int J Infect Dis* 2015;33:28–31, doi:<http://dx.doi.org/10.1016/j.ijid.2014.04.011>.
- Fumaz CR, Munoz-Moreno JA, Molto J, Negro E, Ferrer MJ, Siraera G, Clotet B. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychological issues, and adherence. *J Acquir Immune Defic Syndr* 2005;38(5):560–5.
- Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. *Eur J Clin Pharmacol* 2012;68(5):689–95, doi:<http://dx.doi.org/10.1007/s00228-011-1166-5>.
- Gounden V, van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516G>T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. *AIDS Res Ther* 2010;7:32, doi:<http://dx.doi.org/10.1186/1742-6405-7-32>.
- Hofmann MH, Bliedernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, Zanger UM. Alternative splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6\*6, is responsible for decreased expression and activity of CYP2B6 in liver. *J Pharmacol Exp Ther* 2008;325(1):284–92, doi:<http://dx.doi.org/10.1124/jpet.107.133306>.
- Kerb R, Fux R, Morike K, Kreamsner PG, Gil JP, Gleiter CH, Schwab M. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. *Lancet Infect Dis* 2009;9(12):760–74, doi:[http://dx.doi.org/10.1016/S1473-3099\(09\)70320-2](http://dx.doi.org/10.1016/S1473-3099(09)70320-2).
- King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. *AIDS* 2008;22(14):1709–17, doi:<http://dx.doi.org/10.1097/QAD.0b013e32830163ad>.
- Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Zanger UM. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. *Pharmacogenomics* 2005;15(12):861–73.
- Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6 (c. 516G>T) and CYP2A6 (\*9B and/or \*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. *Br J Clin Pharmacol* 2009;67(4):427–36, doi:<http://dx.doi.org/10.1111/j.1365-2125.2009.03368.x>.
- Kwara A, Tashima KT, Dumond JB, Poethke P, Kurpewski J, Kashuba AD, Greenblatt DJ. Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. *Antimicrob Agents Chemother* 2011;55(7):3527–33, doi:<http://dx.doi.org/10.1128/AAC.00980-10>.
- Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Zanger UM. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. *Pharmacogenetics* 2001;11(5):399–415.
- Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Adult AIDS Clinical Trials Group A5221 Study Team. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. *Clin Infect Dis* 2013;57(4):586–93, doi:<http://dx.doi.org/10.1093/cid/cit246>.
- Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Sungkanuparph S. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug–drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. *Antimicrob Agents Chemother* 2013;57(2):1019–24, doi:<http://dx.doi.org/10.1128/AAC.02023-12>.
- Martin AS, Gomez AI, Garcia-Berrolca B, Figueroa SC, Sanchez MC, Calvo Hernandez MV, Isidoro-Garcia M. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. *Pharmacogenomics* 2014;15(7):997–1006, doi:<http://dx.doi.org/10.2217/pgs.14.48>.
- Marwa KJ, Schmidt T, Sjogren M, Minzi OM, Kamugisha E, Swedberg G. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. *Malar J* 2014;13:420, doi:<http://dx.doi.org/10.1186/1475-2875-13-420>.
- Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. *AIDS* 2001;15(1):71–5.
- Masebe TM, Bessong PO, Nwobegahay J, Ndiip RN, Meyer D. Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients. *Dis Markers* 2012;32(1):43–50, doi:<http://dx.doi.org/10.3233/DMA-2012-0859>.
- Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. *Eur J Clin Pharmacol* 2006;62(4):267–75, doi:<http://dx.doi.org/10.1007/s00228-005-0092-9>.
- Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. *Pharmacol Rev* 2012;64(3):803–33, doi:<http://dx.doi.org/10.1124/pr.111.005553>.
- Ministère de la Santé et de la Population. Ministère de la Santé et de la Population: Politique nationale de lutte contre le paludisme; 2006. Retrieved from Brazzaville, Republic of Congo.
- MOH. Le Fonds mondial Rapport 2017 sur les résultats; 2017. Retrieved from [https://reliefweb.int/sites/reliefweb.int/files/resources/corporate\\_2017resultsreport\\_fr.pdf](https://reliefweb.int/sites/reliefweb.int/files/resources/corporate_2017resultsreport_fr.pdf).
- Mukonzo JK, Roshammar D, Waako P, Andersson M, Fukasawa T, Milani L, Aklillu E. A novel polymorphism in ABCB1 gene, CYP2B6\*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. *Br J Clin Pharmacol* 2009;68(5):690–9, doi:<http://dx.doi.org/10.1111/j.1365-2125.2009.03516.x>.
- Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Burhenne J. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. *PLoS One* 2013;8(7):e67946, doi:<http://dx.doi.org/10.1371/journal.pone.0067946>.
- Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C. High prevalence of the CYP2B6 516G>T(\*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. *Eur J Clin Pharmacol* 2008;64(4):357–65, doi:<http://dx.doi.org/10.1007/s00228-007-0412-3>.
- Paganotti GM, Russo G, Sobze MS, Mayaka GB, Muthoga CW, Tawe L, Vullo V. CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6\*9 and CYP2B6\*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon. *Infect Genet Evol* 2015;35:122–6, doi:<http://dx.doi.org/10.1016/j.meegid.2015.08.003>.
- Ministère de la Santé et de la Population. Programme de Lutte contre la Tuberculose au Congo: Rapport final 2014.
- Pressiat C, Amorissani-Folquet M, Yonaba C, Treluyer JM, Dahourou DL, Eboua F, Hirt D. Pharmacokinetics of efavirenz at a high dose of 25 milligrams per kilogram per day in Children 2 to 3 years old. *Antimicrob Agents Chemother* 2017;61(7), doi:<http://dx.doi.org/10.1128/AAC.00297-17>.
- Rajman I, Knapp L, Morgan T, Masimirembwa C. African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development. *EBioMedicine* 2017;17:67–74, doi:<http://dx.doi.org/10.1016/j.ebiom.2017.02.017>.
- Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. *Expert Opin Drug Metab Toxicol* 2010;6(1):95–103, doi:<http://dx.doi.org/10.1517/17425250903483207>.
- Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Swaminathan S. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. *Antimicrob Agents Chemother* 2009;53(3):863–8, doi:<http://dx.doi.org/10.1128/AAC.00899-08>.
- Read TR, Carey D, Mallon P, Mijch A, Goodall R, Hudson F, Emery S. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. *AIDS* 2009;23(16):2222–3, doi:<http://dx.doi.org/10.1097/QAD.0b013e3283283e95f8>.
- Santé, M.d.I. Rapport national sur la réponse au vih/sida; 2013. Retrieved from [http://www.unaids.org/sites/default/files/country/documents/GAB\\_narrative\\_report\\_2014.pdf](http://www.unaids.org/sites/default/files/country/documents/GAB_narrative_report_2014.pdf).
- Scibona P, Vazquez C, Cajal AR, Argibay PF, Bellosso WH. Prevalence of CYP2B6 polymorphisms in Argentinians: the role of genetic testing. *Genet Mol Res* 2015;14(4):16594–9, doi:<http://dx.doi.org/10.4238/2015.December.11.6>.
- Simonson US, Jansson B, Hai TN, Huang DX, Tybring G, Ashton M. Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. *Clin Pharmacol Ther* 2003;74(1):32–43, doi:[http://dx.doi.org/10.1016/S0009-9236\(03\)00092-4](http://dx.doi.org/10.1016/S0009-9236(03)00092-4).
- Sinxadi PZ, Leger PD, McIlerron HM, Smith PJ, Dave JA, Levitt NS, Haas DW. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. *Br J Clin Pharmacol* 2015;80(1):146–56, doi:<http://dx.doi.org/10.1111/bcp.12590>.
- Staepli Hodel EM, Csajka C, Arie F, Guidi M, Kabanywanyi AM, Duong S, Genton B. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. *Antimicrob Agents Chemother* 2013;57(2):950–8, doi:<http://dx.doi.org/10.1128/AAC.01700-12>.
- Swart M, Evans J, Skelton M, Castel S, Wiesner L, Smith PJ, Dandara C. An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3'-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients. *Front Genet* 2015;6:356, doi:<http://dx.doi.org/10.3389/fgene.2015.00356>.
- Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. *Pharmacogenomics* 2013;23(8):415–27, doi:<http://dx.doi.org/10.1097/FPC.0b013e328363176f>.
- Takahashi M, Ibe S, Kudaya Y, Okumura N, Hirano A, Suzuki T, Kaneda T. No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART. *AIDS Res Hum Retroviruses* 2007;23(8):983–7, doi:<http://dx.doi.org/10.1089/aid.2006.0193>.

- Telenti A, Zanger UM. Pharmacogenetics of anti-HIV drugs. *Annu Rev Pharmacol Toxicol* 2008;48:227–56, doi:<http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094753>.
- Tozzi V. Pharmacogenetics of antiretrovirals. *Antiviral Res* 2010;85(1):190–200, doi:<http://dx.doi.org/10.1016/j.antiviral.2009.09.001>.
- Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. *J Int AIDS Soc* 2013;16:1–14, doi:<http://dx.doi.org/10.7448/IAS.16.1.18567>.
- Vo TT, Varghese Gupta S. Role of cytochrome P450 2B6 pharmacogenomics in determining efavirenz-mediated central nervous system toxicity, treatment outcomes, and dosage adjustments in patients with human immunodeficiency virus infection. *Pharmacotherapy* 2016;36(12):1245–54, doi:<http://dx.doi.org/10.1002/phar.1852>.
- Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. *J Pharmacol Exp Ther* 2003;306(1):287–300, doi:<http://dx.doi.org/10.1124/jpet.103.049601>.
- Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, Xin X. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstm1. *PLoS One* 2014;9(1):e85905, doi:<http://dx.doi.org/10.1371/journal.pone.0085905>.
- Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, Aseffa A. Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. *PLoS One* 2008;3(3):e1809, doi:<http://dx.doi.org/10.1371/journal.pone.0001809>.
- Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Aklillu E. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. *PLoS One* 2011;6(12):e27810, doi:<http://dx.doi.org/10.1371/journal.pone.0027810>.
- Zakeri S, Amiri N, Pirahmadi S, Dinparast Djadid N. Genetic variability of CYP2B6 polymorphisms in southeast Iranian population: implications for malaria and HIV/AIDS treatment. *Arch Iran Med* 2014;17(10):685–91 0141710/AIM.009.
- Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther* 2013;138(1):103–41, doi:<http://dx.doi.org/10.1016/j.pharmthera.2012.12.007>.
- Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. *Drug Metab Rev* 2009;41(2):89–295, doi:<http://dx.doi.org/10.1080/03602530902843483>.
- Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. *Clin Pharmacol Ther* 2017;102(4):688–700, doi:<http://dx.doi.org/10.1002/cpt.690>.